Pure Global AI
NCT06331650Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Guangzhou Institute of Respiratory DiseasePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
cadonilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Guangzhou Institute of Respiratory Disease
Location
Guangdong, China
Timeline & enrollment
Phase
Phase 2
Start date
Aug 09, 2023
End date
Oct 01, 2025
Enrollment
30 participants
Primary outcome

Safety assessments and ORR

Summary

To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as the
 first-line treatment for patients with STK11 mutated advanced or postoperative recurrent
 non-small cell lung cancer (NSCLC).

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06331650
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06331650 through Pure Global AI's free database. This Phase 2 trial is sponsored by Guangzhou Institute of Respiratory Disease and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.